Senior Vice President, Clinical Operations

Miriam Cruz serves as Senior Vice President, Clinical Operations for Avenzo Therapeutics. She has more than 25 years of pharmaceutical and biotech experience, most recently serving as Senior Vice President for Turning Point Therapeutics (acquired by Bristol Myers Squibb in August 2022), where she led Clinical Operations, Clinical Trial Supplies and Clinical Outsourcing.

Prior to Turning Point Therapeutics, Ms. Cruz served as the Vice President of Clinical Operations for Viracta Therapeutics where she led clinical operations for the company’s oncology pipeline. Prior to Viracta, she served as the Global Director, Clinical Operations for Halozyme, Inc., where she led the clinical activities for the company’s Phase 3 pivotal Pancreatic Ductal Adenocarcinoma study. She served in Clinical Operations leadership roles for Proteus Digital Health, Eisai Inc., Merck, Schering-Plough Corporation and Sankyo Pharma Development/Daiichi Sankyo.

Ms. Cruz has a B.S. in Biology/Pre-Med from City College of New York and is pursuing an MBA from the University of California San Diego.